4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 64 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $204 | -99.0% | 16 | -98.6% | 0.00% | – |
| Q2 2023 | $20,346 | +5.1% | 1,126 | 0.0% | 0.00% | – |
| Q1 2023 | $19,355 | -44.5% | 1,126 | -28.2% | 0.00% | – |
| Q4 2022 | $34,847 | +190.4% | 1,569 | 0.0% | 0.00% | – |
| Q3 2022 | $12,000 | +9.1% | 1,569 | +111.5% | 0.00% | – |
| Q1 2022 | $11,000 | -99.1% | 742 | -98.7% | 0.00% | -100.0% |
| Q4 2021 | $1,248,000 | -54.9% | 56,939 | -44.6% | 0.00% | -60.0% |
| Q3 2021 | $2,770,000 | – | 102,717 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |